Genprex (GNPX) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free GNPX Stock Alerts $3.11 +0.69 (+28.51%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 8:31 AM | prnewswire.comGenprex to Present at the 2024 BIO International ConventionMay 20, 2024 | msn.comGNPX Stock Earnings: Genprex Beats EPS for Q1 2024May 15, 2024 | markets.businessinsider.comGenprex’s Promising Clinical Trials and Leadership Drive Buy RatingMay 14, 2024 | prnewswire.comGenprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerMay 13, 2024 | markets.businessinsider.comGenprex Appoints Toscano As ChairmanMay 13, 2024 | prnewswire.comGenprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsMay 9, 2024 | finanznachrichten.deGenprex, Inc.: Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 8, 2024 | marketwatch.comGenprex Co-Founder, CEO Rodney Varner Dies of CancerMay 8, 2024 | prnewswire.comGenprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 1, 2024 | prnewswire.comGenprex to Present and Participate at Upcoming May Investor and Industry ConferencesApril 9, 2024 | finance.yahoo.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 9, 2024 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 3, 2024 | markets.businessinsider.comGenprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock UpApril 3, 2024 | prnewswire.comGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerApril 2, 2024 | markets.businessinsider.comGenprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene TherapyApril 2, 2024 | prnewswire.comGenprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemMarch 22, 2024 | prnewswire.comGenprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 21, 2024 | marketwatch.comGenprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8MMarch 20, 2024 | marketwatch.comGenprex Shares Hit 52-Week Low After Direct Offering PricesMarch 19, 2024 | prnewswire.comGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | finanznachrichten.deGenprex, Inc.: Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | prnewswire.comGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 12, 2024 | markets.businessinsider.comGenprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 AntibodiesMarch 12, 2024 | finance.yahoo.comGenprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersMarch 9, 2024 | theglobeandmail.comGenprex (NASDAQ: GNPX) Preclinical Data to be Presented at AACR Annual MeetingMarch 6, 2024 | marketbeat.comTrading was temporarily halted for "GNPX" at 09:03 AM with a stated reason of "LULD pause."March 6, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingFebruary 26, 2024 | theglobeandmail.comGenprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor ConferenceFebruary 7, 2024 | markets.businessinsider.comGenprex To Expand Non-clinical Program To Study TUSC2, NPRL2February 7, 2024 | finance.yahoo.comGenprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsFebruary 6, 2024 | marketwatch.comGenprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso TrialFebruary 6, 2024 | msn.comGenprex Launches Phase 2a Reqorsa Trial ExpansionFebruary 6, 2024 | finance.yahoo.comGenprex to Present at Upcoming BIO CEO & Investor ConferenceFebruary 5, 2024 | finance.yahoo.comGenprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerFebruary 2, 2024 | marketbeat.comTrading was temporarily halted for "GNPX" at 07:02 PM with a stated reason of "News pending."January 31, 2024 | msn.comDow Turns Lower; Federal Reserve Keeps Rates UnchangedJanuary 31, 2024 | msn.comGenprex to effect 1-for-40 reverse stock split to regain Nasdaq complianceJanuary 31, 2024 | finance.yahoo.comGenprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024January 5, 2024 | finanznachrichten.deGenprex, Inc.: Genprex Provides Business Update and Outlook for 2024January 5, 2024 | finance.yahoo.comGenprex Provides Business Update and Outlook for 2024November 23, 2023 | finance.yahoo.comGenprex Granted Orphan Drug Designation in Small Cell Lung CancerNovember 16, 2023 | nz.finance.yahoo.comGenprex, Inc. (GNPX) stock price, news, quote & history – Yahoo FinanceNovember 3, 2023 | finance.yahoo.comGenprex to Present at BIO-Europe 2023November 1, 2023 | finance.yahoo.comGenprex to Present at BIO-Europe 2023 ConferenceOctober 20, 2023 | finance.yahoo.comGenprex Schedules, Hosts Virtual Key Opinion Leader EventOctober 20, 2023 | finance.yahoo.comGenprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"October 6, 2023 | finance.yahoo.comGenprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC ConferenceOctober 4, 2023 | finance.yahoo.comGenprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 21, 2023 | finance.yahoo.comGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLCSeptember 20, 2023 | finanznachrichten.deNetworkNewsWire: Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. GNPX Media Mentions By Week GNPX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNPX News Sentiment▼0.960.76▲Average Medical News Sentiment GNPX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNPX Articles This Week▼31▲GNPX Articles Average Week Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TCRT News Today KALA News Today AYTU News Today TLPH News Today GLYC News Today GLTO News Today NERV News Today TNXP News Today FLGC News Today ORGS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNPX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
